Anika Therapeutics Inc (NAS:ANIK)
$ 17.35 -0.2 (-1.14%) Market Cap: 254.10 Mil Enterprise Value: 219.27 Mil PE Ratio: 0 PB Ratio: 1.42 GF Score: 70/100

Anika Therapeutics Inc at UBS Global Healthcare Conference (Virtual) Transcript

May 19, 2020 / 12:20PM GMT
Release Date Price: $32.6 (-2.92%)
Mallet Njonkem
UBS - Analyst

Good morning, and thank you for coming to the 2020 Virtual UBS Global Healthcare Conference. My name is Mallet Njonkem, and I'm happy to be your host for this session. Our next presenter will be Dr. Cheryl Blanchard, President and CEO; and Sylvia Cheung, Chief Financial Officer from Anika Therapeutics.

A Q&A session will follow immediately after the presentation. (Operator Instructions)

We now turn it over to Cheryl and Sylvia. Thank you.

Cheryl R. Blanchard
Anika Therapeutics, Inc. - President, CEO & Director

Thank you, Mallet. Good morning, everybody. I'd like to thank the UBS team for giving us the opportunity to present today, and I'd also like to thank everybody on the line listening in for your interest in Anika. I'm Cheryl Blanchard, Anika's President and CEO; and with me on the call today is our CFO, Sylvia Cheung, and we're both very excited to speak with you today about Anika.

So if we want to look at Slide 2, I'm going to just sort of walk everybody through the slides today, so we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot